Literature DB >> 20946898

Recommendations for the validation of flow cytometric testing during drug development: II assays.

Denise M O'Hara1, Yuanxin Xu, Zhiyan Liang, Manjula P Reddy, Dianna Y Wu, Virginia Litwin.   

Abstract

Flow cytometry-based assays serve as valuable tools for various aspects of the drug development process ranging from target discovery and characterization to evaluation of responses in a clinical setting. The integrity of the samples and the appropriate selection and characterization of the reagents used in these assays are in themselves challenging. These concerns taken together with the flow-based technology makes the validation of flow cytometry assays a challenging effort. Therefore, apart from summarizing the role of flow cytometry technology in various stages of drug development, this manuscript focuses on recommendations for the validation of methods applying flow cytometry. Information is also provided on the relevant validation parameters for different types of flow cytometry assays to guide the users of this platform. Together, the recommendations and the information on regulatory guidelines provided in this manuscript represent the consensus of all the authors and can assist the flow cytometry user in implementing the appropriate method validation strategies.
Copyright © 2010 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20946898     DOI: 10.1016/j.jim.2010.09.036

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  21 in total

Review 1.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

2.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

3.  A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies.

Authors:  Sabine Ivison; Mehrnoush Malek; Rosa V Garcia; Raewyn Broady; Anne Halpin; Manon Richaud; Rollin F Brant; Szu-I Wang; Mathieu Goupil; Qingdong Guan; Peter Ashton; Jason Warren; Amr Rajab; Simon Urschel; Deepali Kumar; Mathias Streitz; Birgit Sawitzki; Stephan Schlickeiser; Janetta J Bijl; Donna A Wall; Jean-Sebastien Delisle; Lori J West; Ryan R Brinkman; Megan K Levings
Journal:  JCI Insight       Date:  2018-12-06

4.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

5.  Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Authors:  Teri A Oldaker; Paul K Wallace; David Barnett
Journal:  Cytometry B Clin Cytom       Date:  2015-09-04       Impact factor: 3.058

Review 6.  Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.

Authors:  Hannah S Newton; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2022-04-09       Impact factor: 17.873

7.  Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.

Authors:  Kah Teong Soh; Joseph D Tario; Theresa E Hahn; Jens Hillengass; Philip L McCarthy; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2019-12-23       Impact factor: 3.058

8.  Validation of inducible basophil biomarkers: Time, temperature and transportation.

Authors:  Theodore Kim; Jing Yu; Henry Li; Mark Scarupa; Richard L Wasserman; Athena Economides; Martha White; Carla Ward; Atul Shah; Douglas Jones; Melinda Rathkopf; Kelly Frye; Ahmet Aybar; Shahrooz Shayegan; Benjamin Enav; Laura Ispas; Denise Loizou; David Fitzhugh; James Tracy; James Friedlander; Zachary Jacobs; Jonathan Matz; David Golden; Donald McNeil; William McCann; Christopher Copenhaver; Jeffrey Factor; Raavi Gupta; Oral Alpan; Matthew Plassmeyer; Søren Ulrik Sønder
Journal:  Cytometry B Clin Cytom       Date:  2021-02-04       Impact factor: 3.248

9.  Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response.

Authors:  Chi-Chih Kang; Jung-Ming G Lin; Zhuchen Xu; Sanjay Kumar; Amy E Herr
Journal:  Anal Chem       Date:  2014-10-01       Impact factor: 6.986

10.  Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications.

Authors:  Behnam Ahmadian Baghbaderani; Adhikarla Syama; Renuka Sivapatham; Ying Pei; Odity Mukherjee; Thomas Fellner; Xianmin Zeng; Mahendra S Rao
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.